1. Mitra AR, Fergusson NA, Lloyd-Smith E, et al. Baseline characteristics and outcomes of patients with COVID-19 admitted to intensive care units in Vancouver, Canada: a case series [published online ahead of print, 2020 May 27]. CMAJ. 2020;cmaj.200794. doi:10.1503/cmaj.200794
2. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. Published 2020 May 14. doi:10.1183/13993003.00547-2020
3. Porcheddu R, Serra C, Kelvin D, Kelvin N, Rubino S. Similarity in Case Fatality Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China. J Infect Dev Ctries. 2020;14(2):125‐128. Published 2020 Feb 29. doi:10.3855/jidc.12600
4. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention [published online ahead of print, 2020 Feb 24]. JAMA. 2020;10.1001/jama.2020.2648. doi:10.1001/jama.2020.2648
5. Wang B, Li R, Lu Z, Huang Y. Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis. Aging (Albany NY). 2020;12(7):6049‐6057. doi:10.18632/aging.103000
6. Nikpouraghdam M, Jalali Farahani A, Alishiri G, et al. Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in IRAN: A single center study. J Clin Virol. 2020; 127:104378. doi:10.1016/j.jcv.2020.104378
7. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study [published correction appears in Lancet Respir Med. 2020 Apr;8(4):e26]. Lancet Respir Med. 2020;8(5):475‐481. doi:10.1016/S2213-2600(20)30079-5
8. Guo T, Fan Y, Chen M, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) [published online ahead of print, 2020 Mar 27]. JAMA Cardiol. 2020; e201017. doi:10.1001/jamacardio.2020.1017
9. Dariya B, Nagaraju GP. Understanding novel COVID-19: Its impact on organ failure and risk assessment for diabetic and cancer patients [published online ahead of print, 2020 May 6]. Cytokine Growth Factor Rev. 2020; S1359-6101(20)30078-2. doi:10.1016/j.cytogfr.2020.05.001
10. Durvasula R, Wellington T, McNamara E, Watnick S. COVID-19 and Kidney Failure in the Acute Care Setting: Our Experience From Seattle [published online ahead of print, 2020 Apr 8]. Am J Kidney Dis. 2020; S0272-6386(20)30618-1. doi:10.1053/j.ajkd.2020.04.001
11. Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829‐838. doi:10.1016/j.kint.2020.03.005
12. Ni W, Yang X, Liu J, et al. Acute Myocardial Injury at Hospital Admission is Associated with All-cause Mortality in COVID-19 [published online ahead of print, 2020 May 8]. J Am Coll Cardiol. 2020; S0735-1097(20)35225-6. doi:10.1016/j.jacc.2020.05.007
13. Pei G, Zhang Z, Peng J, et al. Renal Involvement and Early Prognosis in Patients with COVID-19 Pneumonia. J Am Soc Nephrol. 2020;31(6):1157‐1165. doi:10.1681/ASN.2020030276
14. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708‐1720. doi:10.1056/NEJMoa2002032
15. Yang K, Sheng Y, Huang C, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study [published online ahead of print, 2020 May 29]. Lancet Oncol. 2020;S1470-2045(20)30310-7. doi:10.1016/S1470-2045(20)30310-7
16. National Health Commission of the People’s Republic of China. Chinese management guideline for COVID-19 (version 5.0).
17. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. Accessed on May 30, 2020.
18. Damman K, Perez AC, Anand IS, et al. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment. J Am Coll Cardiol. 2014;64(11):1106‐1113. doi:10.1016/j.jacc.2014.01.087
19. Wang D, Yin Y, Hu C, et al. Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China. Crit Care. 2020;24(1):188. Published 2020 Apr 30. doi:10.1186/s13054-020-02895-6
20. Preacher KJ, Hayes AF. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav Res Methods. 2008;40(3):879‐891. doi:10.3758/brm.40.3.879
21. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet. 2020 Mar 28;395(10229):1038] [published correction appears in Lancet. 2020 Mar 28;395(10229):1038]. Lancet. 2020;395(10229):1054‐1062. doi:10.1016/S0140-6736(20)30566-3
22. Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):458‐464. Published 2020 Apr 17. doi:10.15585/mmwr.mm6915e3
23. Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area [published online ahead of print, 2020 Apr 22] [published correction appears in doi: 10.1001/jama.2020.7681]. JAMA. 2020;323(20):2052‐2059. doi:10.1001/jama.2020.6775
24. Wang X, Fang X, Cai Z, et al. Comorbid Chronic Diseases and Acute Organ Injuries Are Strongly Correlated with Disease Severity and Mortality among COVID-19 Patients: A Systemic Review and Meta-Analysis. Research (Wash D C). 2020; 2020:2402961. Published 2020 Apr 19. doi:10.34133/2020/2402961
25. Naicker S, Yang CW, Hwang SJ, Liu BC, Chen JH, Jha V. The Novel Coronavirus 2019 epidemic and kidneys. Kidney Int. 2020;97(5):824‐828. doi:10.1016/j.kint.2020.03.001
26. Rabb H. Kidney diseases in the time of COVID-19: major challenges to patient care. J Clin Invest. 2020;130(6):2749‐2751. doi:10.1172/JCI138871
27. Matricardi PM, Dal Negro RW, Nisini R. The first, holistic immunological model of COVID-19: implications for prevention, diagnosis, and public health measures [published online ahead of print, 2020 May 2]. Pediatr Allergy Immunol. 2020;10.1111/pai.13271. doi:10.1111/pai.13271 Groß S, Jahn C, Cushman S, Bär C, Thum T. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications [published online ahead of print, 2020 Apr 30]. J Mol Cell Cardiol. 2020; 144:47‐53. doi:10.1016/j.yjmcc.2020.04.031
28. Groß S, Jahn C, Cushman S, Bär C, Thum T. SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications [published online ahead of print, 2020 Apr 30]. J Mol Cell Cardiol. 2020; 144:47‐53. doi:10.1016/j.yjmcc.2020.04.031
29. Saavedra JM. Angiotensin receptor blockers and COVID-19. Pharmacol Res. 2020; 156:104832. doi:10.1016/j.phrs. 2020.104832
30. Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875‐879. doi:10.1038/nm1267
31. Frost DW, Shah R, Melvin L, et al. Principles for clinical care of patients with COVID-19 on medical units [published online ahead of print, 2020 Jun 3].CMAJ. 2020;cmaj.200855. doi:10.1503/cmaj.200855